FI89065C - Foerfarande foer framstaellning av en ny siklosporin kristallform - Google Patents

Foerfarande foer framstaellning av en ny siklosporin kristallform Download PDF

Info

Publication number: FI89065C
Authority: FI; Finland
Prior art keywords: iii; cyclosporin; treatment; cyclosporine; formulations
Prior art date: 1987-12-21

Application number

FI885869A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI885869A0 (fi

FI885869L (fi

FI89065B (fi

Inventor

Danielle Giron

Martin List

Friedrich Richter

Yasuyuki Uike

Hans Peter Weber

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-12-21

Filing date

1988-12-19

Publication date

1993-09-30

1988-12-19 Application filed by Sandoz Ag filed Critical Sandoz Ag

1988-12-19 Publication of FI885869A0 publication Critical patent/FI885869A0/fi

1989-06-22 Publication of FI885869L publication Critical patent/FI885869L/fi

1993-04-30 Publication of FI89065B publication Critical patent/FI89065B/fi

1993-09-30 Application granted granted Critical

1993-09-30 Publication of FI89065C publication Critical patent/FI89065C/fi

Links

238000005057 refrigeration Methods 0.000 title 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 133
108010036949 Cyclosporine Proteins 0.000 claims description 132
229960001265 ciclosporin Drugs 0.000 claims description 130
229930182912 cyclosporin Natural products 0.000 claims description 104
229930105110 Cyclosporin A Natural products 0.000 claims description 63
238000000034 method Methods 0.000 claims description 38
239000013078 crystal Substances 0.000 claims description 34
238000002360 preparation method Methods 0.000 claims description 33
229920001223 polyethylene glycol Polymers 0.000 claims description 23
230000008569 process Effects 0.000 claims description 10
239000002904 solvent Substances 0.000 claims description 9
238000002441 X-ray diffraction Methods 0.000 claims description 7
239000004698 Polyethylene Substances 0.000 claims description 3
229920001451 polypropylene glycol Polymers 0.000 claims description 3
150000002170 ethers Chemical class 0.000 claims description 2
239000000203 mixture Substances 0.000 description 92
238000011282 treatment Methods 0.000 description 68
239000002245 particle Substances 0.000 description 51
238000009472 formulation Methods 0.000 description 45
230000000699 topical effect Effects 0.000 description 27
201000004681 Psoriasis Diseases 0.000 description 26
239000000047 product Substances 0.000 description 25
239000007924 injection Substances 0.000 description 22
238000002347 injection Methods 0.000 description 22
238000012360 testing method Methods 0.000 description 20
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
229940068196 placebo Drugs 0.000 description 18
239000000902 placebo Substances 0.000 description 18
230000003902 lesion Effects 0.000 description 17
239000003814 drug Substances 0.000 description 16
-1 e.g. Substances 0.000 description 16
238000002474 experimental method Methods 0.000 description 16
239000000499 gel Substances 0.000 description 16
239000002202 Polyethylene glycol Substances 0.000 description 15
201000010099 disease Diseases 0.000 description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
229940079593 drug Drugs 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
239000004615 ingredient Substances 0.000 description 12
238000012986 modification Methods 0.000 description 12
230000004048 modification Effects 0.000 description 12
239000006071 cream Substances 0.000 description 11
239000000463 material Substances 0.000 description 11
239000000243 solution Substances 0.000 description 11
230000002500 effect on skin Effects 0.000 description 10
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 10
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 10
239000000126 substance Substances 0.000 description 10
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
206010015150 Erythema Diseases 0.000 description 9
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
238000002425 crystallisation Methods 0.000 description 9
230000008025 crystallization Effects 0.000 description 9
231100000321 erythema Toxicity 0.000 description 9
239000007788 liquid Substances 0.000 description 9
238000003756 stirring Methods 0.000 description 9
239000004094 surface-active agent Substances 0.000 description 9
238000005809 transesterification reaction Methods 0.000 description 9
229920003171 Poly (ethylene oxide) Polymers 0.000 description 8
239000003921 oil Substances 0.000 description 8
230000009467 reduction Effects 0.000 description 8
230000000694 effects Effects 0.000 description 7
238000000227 grinding Methods 0.000 description 7
239000013081 microcrystal Substances 0.000 description 7
235000019198 oils Nutrition 0.000 description 7
229940100688 oral solution Drugs 0.000 description 7
235000019271 petrolatum Nutrition 0.000 description 7
229940068886 polyethylene glycol 300 Drugs 0.000 description 7
239000000725 suspension Substances 0.000 description 7
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 6
206010012438 Dermatitis atopic Diseases 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
201000008937 atopic dermatitis Diseases 0.000 description 6
239000002775 capsule Substances 0.000 description 6
239000000839 emulsion Substances 0.000 description 6
239000003925 fat Substances 0.000 description 6
239000007903 gelatin capsule Substances 0.000 description 6
235000011187 glycerol Nutrition 0.000 description 6
239000006186 oral dosage form Substances 0.000 description 6
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
229920000136 polysorbate Polymers 0.000 description 6
229920000053 polysorbate 80 Polymers 0.000 description 6
238000007127 saponification reaction Methods 0.000 description 6
239000003381 stabilizer Substances 0.000 description 6
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
206010033078 Otitis media Diseases 0.000 description 5
208000003251 Pruritus Diseases 0.000 description 5
239000004599 antimicrobial Substances 0.000 description 5
230000001363 autoimmune Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
239000006185 dispersion Substances 0.000 description 5
238000009826 distribution Methods 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
235000019197 fats Nutrition 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
239000011630 iodine Substances 0.000 description 5
229910052740 iodine Inorganic materials 0.000 description 5
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 5
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 5
229960002216 methylparaben Drugs 0.000 description 5
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 5
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 5
229960003415 propylparaben Drugs 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000012453 solvate Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
235000015112 vegetable and seed oil Nutrition 0.000 description 5
239000008158 vegetable oil Substances 0.000 description 5
LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 4
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical class CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
201000004384 Alopecia Diseases 0.000 description 4
206010010741 Conjunctivitis Diseases 0.000 description 4
206010012442 Dermatitis contact Diseases 0.000 description 4
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
229920001214 Polysorbate 60 Polymers 0.000 description 4
230000003111 delayed effect Effects 0.000 description 4
238000004090 dissolution Methods 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
238000000265 homogenisation Methods 0.000 description 4
230000001506 immunosuppresive effect Effects 0.000 description 4
230000006872 improvement Effects 0.000 description 4
230000006911 nucleation Effects 0.000 description 4
238000010899 nucleation Methods 0.000 description 4
239000004006 olive oil Substances 0.000 description 4
235000008390 olive oil Nutrition 0.000 description 4
239000008389 polyethoxylated castor oil Substances 0.000 description 4
230000001185 psoriatic effect Effects 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
238000011200 topical administration Methods 0.000 description 4
239000003871 white petrolatum Substances 0.000 description 4
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 3
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
208000023275 Autoimmune disease Diseases 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
208000003556 Dry Eye Syndromes Diseases 0.000 description 3
206010013774 Dry eye Diseases 0.000 description 3
208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
208000022873 Ocular disease Diseases 0.000 description 3
235000019483 Peanut oil Nutrition 0.000 description 3
239000004264 Petrolatum Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000002917 arthritic effect Effects 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
235000019445 benzyl alcohol Nutrition 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
208000010247 contact dermatitis Diseases 0.000 description 3
RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 3
238000010586 diagram Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000008394 flocculating agent Substances 0.000 description 3
208000024963 hair loss Diseases 0.000 description 3
230000003676 hair loss Effects 0.000 description 3
238000001802 infusion Methods 0.000 description 3
201000006417 multiple sclerosis Diseases 0.000 description 3
239000002674 ointment Substances 0.000 description 3
239000000312 peanut oil Substances 0.000 description 3
229940066842 petrolatum Drugs 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
230000000704 physical effect Effects 0.000 description 3
229920001281 polyalkylene Polymers 0.000 description 3
229920005862 polyol Polymers 0.000 description 3
150000003077 polyols Chemical class 0.000 description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
230000003578 releasing effect Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
208000017520 skin disease Diseases 0.000 description 3
239000011734 sodium Substances 0.000 description 3
238000000527 sonication Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 2
LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
235000019489 Almond oil Nutrition 0.000 description 2
206010003645 Atopy Diseases 0.000 description 2
208000002691 Choroiditis Diseases 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
208000012659 Joint disease Diseases 0.000 description 2
206010029164 Nephrotic syndrome Diseases 0.000 description 2
240000007594 Oryza sativa Species 0.000 description 2
235000007164 Oryza sativa Nutrition 0.000 description 2
235000019482 Palm oil Nutrition 0.000 description 2
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 2
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 2
208000003971 Posterior uveitis Diseases 0.000 description 2
208000025747 Rheumatic disease Diseases 0.000 description 2
206010040867 Skin hypertrophy Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
239000008168 almond oil Substances 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000000084 colloidal system Substances 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000002285 corn oil Substances 0.000 description 2
235000005687 corn oil Nutrition 0.000 description 2
210000004087 cornea Anatomy 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000009977 dual effect Effects 0.000 description 2
230000002996 emotional effect Effects 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
230000002538 fungal effect Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
230000035876 healing Effects 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
239000012051 hydrophobic carrier Substances 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
229940125721 immunosuppressive agent Drugs 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
229940057995 liquid paraffin Drugs 0.000 description 2
230000005923 long-lasting effect Effects 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 2
239000002540 palm oil Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000006072 paste Substances 0.000 description 2
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
229960002036 phenytoin Drugs 0.000 description 2
229920001515 polyalkylene glycol Polymers 0.000 description 2
229940068965 polysorbates Drugs 0.000 description 2
230000002265 prevention Effects 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
235000009566 rice Nutrition 0.000 description 2
238000005096 rolling process Methods 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000006748 scratching Methods 0.000 description 2
230000002393 scratching effect Effects 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000001384 succinic acid Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000008719 thickening Effects 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
239000012049 topical pharmaceutical composition Substances 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 1
JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
241001550224 Apha Species 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
235000017060 Arachis glabrata Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
235000010777 Arachis hypogaea Nutrition 0.000 description 1
235000018262 Arachis monticola Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010010264 Condition aggravated Diseases 0.000 description 1
206010010744 Conjunctivitis allergic Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
229910016523 CuKa Inorganic materials 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
206010061958 Food Intolerance Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000023661 Haematological disease Diseases 0.000 description 1
208000004898 Herpes Labialis Diseases 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
201000002287 Keratoconus Diseases 0.000 description 1
208000001126 Keratosis Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
206010068773 Mechanical urticaria Diseases 0.000 description 1
229920003102 Methocel™ E4M Polymers 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
206010067152 Oral herpes Diseases 0.000 description 1
206010033546 Pallor Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
241000218657 Picea Species 0.000 description 1
229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
108010002885 Polygeline Proteins 0.000 description 1
229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229920001219 Polysorbate 40 Polymers 0.000 description 1
108010013381 Porins Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229920001304 Solutol HS 15 Polymers 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
206010048222 Xerosis Diseases 0.000 description 1
IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
208000002029 allergic contact dermatitis Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000009285 allergic inflammation Effects 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
238000002266 amputation Methods 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
229940125687 antiparasitic agent Drugs 0.000 description 1
239000003904 antiprotozoal agent Substances 0.000 description 1
238000000429 assembly Methods 0.000 description 1
230000000712 assembly Effects 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229940074979 cetyl palmitate Drugs 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
238000012864 cross contamination Methods 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000000881 depressing effect Effects 0.000 description 1
201000000409 dermatographia Diseases 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000006196 drop Substances 0.000 description 1
201000002545 drug psychosis Diseases 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
208000020157 familial dermatographia Diseases 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
150000002194 fatty esters Chemical class 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
238000001879 gelation Methods 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000013038 hand mixing Methods 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
206010021198 ichthyosis Diseases 0.000 description 1
208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
230000007803 itching Effects 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000006651 lactation Effects 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
239000004571 lime Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229920003087 methylethyl cellulose Polymers 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
238000003801 milling Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
231100000381 nephrotoxic Toxicity 0.000 description 1
210000002445 nipple Anatomy 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
229940046781 other immunosuppressants in atc Drugs 0.000 description 1
239000003973 paint Substances 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
235000011837 pasties Nutrition 0.000 description 1
235000020232 peanut Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000003209 petroleum derivative Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
230000019612 pigmentation Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
102000007739 porin activity proteins Human genes 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000000634 powder X-ray diffraction Methods 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000009597 pregnancy test Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229940063122 sandimmune Drugs 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
230000037380 skin damage Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
235000011078 sorbitan tristearate Nutrition 0.000 description 1
239000001589 sorbitan tristearate Substances 0.000 description 1
229960004129 sorbitan tristearate Drugs 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000035900 sweating Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000006257 total synthesis reaction Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
201000005539 vernal conjunctivitis Diseases 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

FI885869A 1987-12-21 1988-12-19 Foerfarande foer framstaellning av en ny siklosporin kristallform FI89065C (fi)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date
US13623087A	1987-12-21	1987-12-21
US13623087		1987-12-21
US17261388A	1988-03-24	1988-03-24
US17261388		1988-03-24
US21254888A	1988-06-28	1988-06-28
US21254888		1988-06-28

Publications (4)

Publication Number	Publication Date
FI885869A0 FI885869A0 (fi)	1988-12-19
FI885869L FI885869L (fi)	1989-06-22
FI89065B FI89065B (fi)	1993-04-30
FI89065C true FI89065C (fi)	1993-09-30

Family

ID=27384838

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI885869A FI89065C (fi)	1987-12-21	1988-12-19	Foerfarande foer framstaellning av en ny siklosporin kristallform

Country Status (27)

Country	Link
JP (1)	JPH0791316B2 (da)
KR (1)	KR100188305B1 (da)
AT (1)	AT403163B (da)
AU (1)	AU626274B2 (da)
BE (1)	BE1002665A4 (da)
CA (1)	CA1341396C (da)
CH (1)	CH677926A5 (da)
CY (1)	CY1799A (da)
DE (1)	DE3843054C2 (da)
DK (1)	DK175220B1 (da)
ES (1)	ES2012580A6 (da)
FI (1)	FI89065C (da)
FR (1)	FR2624863B1 (da)
GB (1)	GB2211848B (da)
GR (1)	GR1002486B (da)
HK (1)	HK102894A (da)
HU (1)	HU203564B (da)
IE (1)	IE62006B1 (da)
IL (1)	IL88719A0 (da)
IT (1)	IT1235356B (da)
LU (1)	LU87409A1 (da)
MY (1)	MY103943A (da)
NL (1)	NL195096C (da)
NO (1)	NO177228C (da)
NZ (1)	NZ227384A (da)
SE (1)	SE503174C2 (da)
SG (1)	SG99494G (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5639724A (en)	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
GB2222770B (en) *	1988-09-16	1992-07-29	Sandoz Ltd	Pharmaceutical compositions containing cyclosporins
US6007840A (en) *	1988-09-16	1999-12-28	Novartis Ag	Pharmaceutical compositions comprising cyclosporins
US7081445B2 (en)	1989-02-20	2006-07-25	Novartis Ag	Cyclosporin galenic forms
US5294604A (en) *	1989-12-20	1994-03-15	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating ocular diseases by periocular administration of cyclosporine A or G
GB9105705D0 (en) *	1991-03-18	1991-05-01	Sandoz Ltd	Improvements in or relating to organic compounds
US6262022B1 (en)	1992-06-25	2001-07-17	Novartis Ag	Pharmaceutical compositions containing cyclosporin as the active agent
SG45449A1 (en) *	1992-05-13	1998-01-16	Sandoz Ltd	Ophthalmic compositions
DK0589843T3 (da)	1992-09-25	2002-04-02	Novartis Ag	Cyclosporinholdige farmaceutiske præparater
ATE218359T1 (de)	1994-11-03	2002-06-15	Novartis Erfind Verwalt Gmbh	Neue zubereitungsformen des cyclosporins zur oralen applikation mit einfacher zusammensetzung und hoher bioverfügbarkeit und verfahren zu deren herstellung
US5962019A (en) *	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
US5766629A (en)	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
DE19544507B4 (de)	1995-11-29	2007-11-15	Novartis Ag	Cyclosporin enthaltende Präparate
US6262054B1 (en) *	1996-02-01	2001-07-17	Sloan-Kettering Institute Of Cancer Research	Combination therapy method for treating breast cancer using edatrexate
PT988046E (pt)	1997-01-30	2004-12-31	Novartis Ag	Composicoes farmaceuticas sem oleo contendo ciclosporina a
TW581681B (en)	1998-02-20	2004-04-01	Nektar Therapeutics	Liquid crystal forms of cyclosporin
US7732404B2 (en)	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin
EP1706095B1 (en)	2004-01-20	2008-12-24	Allergan, Inc.	Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
CN1763084B (zh) *	2005-10-11	2010-04-21	山东新时代药业有限公司	高纯度环孢菌素a的制备方法
UA113627C2 (xx)	2011-05-27	2017-02-27		Кристалічна форма циклоспорину a, фармацевтична композиція та спосіб лікування
JP6363506B2 (ja)	2011-11-15	2018-07-25	アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ	シクロスポリンａ２型の懸濁剤
CN108714137B (zh) *	2011-11-15	2022-02-01	阿勒根公司	环孢菌素a形式2的可热压性悬浮液
CN104039813B (zh)	2011-11-15	2017-08-29	阿勒根公司	环孢菌素a形式2及其制备方法
KR102029513B1 (ko) *	2011-11-15	2019-10-07	알러간, 인코포레이티드	사이클로스포린 제2형의 지속 작용 제형
US20260132169A1 (en) *	2022-10-20	2026-05-14	Chugai Seiyaku Kabushiki Kaisha	Method for producing cyclic peptide crystals

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH614931A5 (da) *	1975-11-04	1979-12-28	Sandoz Ag
CH640519A5 (en) *	1976-04-09	1984-01-13	Sandoz Ag	Process for preparing a modified form of the antibiotic S 7481/F-1
US4117118A (en) *	1976-04-09	1978-09-26	Sandoz Ltd.	Organic compounds
DE2819094A1 (de) *	1977-05-10	1978-11-23	Sandoz Ag	Cyclosporin-derivate, ihre verwendung und herstellung
CH637124A5 (en) *	1978-10-18	1983-07-15	Sandoz Ag	Antibiotic, its preparation and use

1988
- 1988-12-09 HU HU886374A patent/HU203564B/hu unknown
- 1988-12-19 FR FR888816886A patent/FR2624863B1/fr not_active Expired - Lifetime
- 1988-12-19 GB GB8829556A patent/GB2211848B/en not_active Expired - Lifetime
- 1988-12-19 SE SE8804570A patent/SE503174C2/sv not_active IP Right Cessation
- 1988-12-19 FI FI885869A patent/FI89065C/fi not_active IP Right Cessation
- 1988-12-19 DK DK198807054A patent/DK175220B1/da not_active IP Right Cessation
- 1988-12-19 AU AU27055/88A patent/AU626274B2/en not_active Expired
- 1988-12-19 NZ NZ227384A patent/NZ227384A/xx unknown
- 1988-12-19 IL IL88719A patent/IL88719A0/xx unknown
- 1988-12-19 IE IE377988A patent/IE62006B1/en not_active IP Right Cessation
- 1988-12-19 NO NO885625A patent/NO177228C/no unknown
- 1988-12-19 CH CH4687/88A patent/CH677926A5/de not_active IP Right Cessation
- 1988-12-20 AT AT0309588A patent/AT403163B/de not_active IP Right Cessation
- 1988-12-20 JP JP63321857A patent/JPH0791316B2/ja not_active Expired - Lifetime
- 1988-12-20 KR KR1019880017194A patent/KR100188305B1/ko not_active Expired - Lifetime
- 1988-12-20 LU LU87409A patent/LU87409A1/fr unknown
- 1988-12-20 IT IT8848690A patent/IT1235356B/it active
- 1988-12-20 BE BE8801421A patent/BE1002665A4/fr not_active IP Right Cessation
- 1988-12-20 GR GR880100850A patent/GR1002486B/el not_active IP Right Cessation
- 1988-12-21 CA CA000586611A patent/CA1341396C/en not_active Expired - Fee Related
- 1988-12-21 DE DE3843054A patent/DE3843054C2/de not_active Expired - Lifetime
- 1988-12-21 MY MYPI88001495A patent/MY103943A/en unknown
- 1988-12-21 NL NL8803125A patent/NL195096C/nl active Search and Examination
- 1988-12-21 ES ES8803887A patent/ES2012580A6/es not_active Expired - Lifetime
1994
- 1994-07-21 SG SG99494A patent/SG99494G/en unknown
- 1994-09-22 HK HK102894A patent/HK102894A/xx not_active IP Right Cessation
1995
- 1995-02-17 CY CY179995A patent/CY1799A/en unknown

Also Published As

Publication number	Publication date
SE503174C2 (sv)	1996-04-15
AU2705588A (en)	1989-06-22
NZ227384A (en)	1991-09-25
NL195096C (nl)	2004-02-09
FI885869A0 (fi)	1988-12-19
NL8803125A (nl)	1989-07-17
CA1341396C (en)	2002-11-05
IE883779L (en)	1989-06-21
SE8804570D0 (sv)	1988-12-19
NO177228B (no)	1995-05-02
ATA309588A (de)	1997-04-15
LU87409A1 (fr)	1989-07-07
FI885869L (fi)	1989-06-22
FI89065B (fi)	1993-04-30
AT403163B (de)	1997-11-25
HUT49893A (en)	1989-11-28
SG99494G (en)	1994-10-28
KR100188305B1 (ko)	1999-06-01
GR1002486B (el)	1996-12-09
NO885625D0 (no)	1988-12-19
GB2211848A (en)	1989-07-12
IT8848690A0 (it)	1988-12-20
GB2211848B (en)	1991-11-06
IL88719A0 (en)	1989-07-31
SE8804570L (sv)	1989-06-22
GR880100850A (el)	1994-03-31
DE3843054C2 (de)	2003-08-21
BE1002665A4 (fr)	1991-04-30
JPH0791316B2 (ja)	1995-10-04
DK175220B1 (da)	2004-07-12
KR890009975A (ko)	1989-08-05
NO885625L (no)	1989-06-22
MY103943A (en)	1993-10-30
JPH01211598A (ja)	1989-08-24
CH677926A5 (da)	1991-07-15
AU626274B2 (en)	1992-07-30
NO177228C (no)	1995-08-09
CY1799A (en)	1995-02-17
HU203564B (en)	1991-08-28
DK705488A (da)	1989-06-22
FR2624863A1 (fr)	1989-06-23
HK102894A (en)	1994-09-30
FR2624863B1 (fr)	1991-04-26
DK705488D0 (da)	1988-12-19
ES2012580A6 (es)	1990-04-01
DE3843054A1 (de)	1989-07-27
IT1235356B (it)	1992-06-30
GB8829556D0 (en)	1989-02-08
IE62006B1 (en)	1994-12-14

Legal Events

Date	Code	Title	Description
1988-12-19	FG	Patent granted	Owner name: NOVARTIS AG
1993-04-01	BB	Publication of examined application
1997-09-03	PC	Transfer of assignment of patent	Owner name: NOVARTIS AG
2004-08-31	FG	Patent granted	Owner name: NOVARTIS AG
2009-01-20	MA	Patent expired

Publication	Publication Date	Title
AU626274B2 (en)	1992-07-30	New ciclosporin crystal form, processes for its production, pharmaceutical compositions containing it and its use.
US6486124B2 (en)	2002-11-26	Cyclosporin compositions and process therefor
AT403435B (de)	1998-02-25	Cyclosporin enthaltende pharmazeutische zusammensetzung
HUT73664A (en)	1996-09-30	Pharmaceutically acceptable improved compositions containing an alcohol and a hydrophobic drug
JPH02255623A (ja)	1990-10-16	新規シクロスポリン製剤
CA2181422A1 (fr)	1997-01-28	Formulations galeniques du fenofibrate et leurs applications
FI94837B (fi)	1995-07-31	Vesiliukoisia monoestereitä käytettäväksi farmakologisesti aktiivisten yhdisteiden kantajana ja farmaseuttisten apuaineiden liukoisuutta lisäävinä aineina
JP2948111B2 (ja)	1999-09-13	経口投与用油性組成物
CZ847488A3 (en)	1995-02-15	Process for preparing cyclosporin a
ZA200104828B (en)	2002-09-13	Cyclosporin solution.
HU212727B (en)	1996-10-28	Process for producing pharmaceutical compositions in form of microemulsion-prae-concentrate or microemulsion containing cyclosporin(s) as active component